FINHUB Insights

JNJ · Q1 FY26 · Dec 29, 2025 – Mar 29, 2026

Johnson & Johnson Q1 FY26: where the revenue came from and where it went

Johnson & Johnson Q1 FY26: revenue $24.1B (+10% year over year). Net profit $5.2B. Largest cohort Innovative Medicine $15.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Dec 29, 2025 – Mar 29, 2026
Reported
Apr 22, 2026 10-Q
Sankey diagram of Johnson & Johnson's income statement for Q1 FY26: revenue of $24.1 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$24.1B +10% year over year
Gross profit$16B 66% margin
Operating profit$6.4B 27% margin
Net profit$5.2B 22% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 29, 2026).
ItemValueShare of revenueYear over year
Revenue 24.1 100% +10%
Innovative Medicine 15.4 64% +11%
Med Tech 8.6 36% +8%
Cost of revenue−8.134%
Gross profit1666% margin+0pp
SG&A−625%+2pp
Other−3.515%+0pp
Operating profit6.427% margin+0pp
Tax−0.8
Interest & other costs−0.4
Net profit5.222%−28pp
Filing on EDGAR More quarters of JNJ

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters